Story perspectives

FDA Cracks Down on Misleading Drug Ads with Warning Letters

9/19/2025

50 12

Summary

Story summary

The FDA issued hundreds of warning letters and 100 cease and desist orders against misleading pharmaceutical advertisements, indicating a significant enforcement shift.
This includes campaigns for GLP-1 drugs like Mounjaro and Zepbound, and an Oprah Winfrey special that minimized safety risks.
The FDA's actions mark the strongest stance on drug advertising in over a decade, with no letters in 2024 and only one in 2023.
New advertising rules may enhance oversight of traditional and digital platforms to restore public trust in pharmaceutical communications.
Companies risk reputational damage if their ads are seen as intentionally misleading, reflecting a shift in the relationship between the pharmaceutical industry, regulators, and the public.

1 of 1

Story summary

The FDA issued hundreds of warning letters and 100 cease and desist orders against misleading pharmaceutical advertisements, indicating a significant enforcement shift.
This includes campaigns for GLP-1 drugs like Mounjaro and Zepbound, and an Oprah Winfrey special that minimized safety risks.
The FDA's actions mark the strongest stance on drug advertising in over a decade, with no letters in 2024 and only one in 2023.
New advertising rules may enhance oversight of traditional and digital platforms to restore public trust in pharmaceutical communications.
Companies risk reputational damage if their ads are seen as intentionally misleading, reflecting a shift in the relationship between the pharmaceutical industry, regulators, and the public.